Dr. Thierry Le Bihan Joins Rapid Novor Inc. to Further Advance Antibody Protein Sequencing Technologies

KITCHENER, Canada, March 1, 2018 /PRNewswire-iReach/ -- Rapid Novor Inc., the world's leader in antibody protein sequencing using mass spectrometry, today announces that Dr. Thierry Le Bihan has joined the team as a Senior Scientist.

Prior to joining Rapid Novor, Dr. Le Bihan was a senior lecturer at The University of Edinburgh (UK), where he undertook research to analyze complex proteomic samples using LC-MS/MS platforms. He is an expert in developing various quantitative labeling and label-free strategies for mass spectrometry.

As the Director of the Proteomics Facility at The Campbell Family Institute for Breast Cancer Research at The Princess Margaret Cancer Centre, Dr. Le Bihan led a multi-functional research team to support several cancer research projects.

Prior to returning to academia, Dr. Le Bihan was a research scientist at MDS Proteomics, where he led a team of scientists developing a mass spectrometry platform for several biomarker projects. 

"We are thrilled to have such an accomplished scientist joining our team to help us further advance our antibody protein sequencing technologies," says Mingjie Xie, co-founder and CEO. "We now have more capacity to take on new project initiatives and advance our technology development faster. Thierry's more than 20 years of experience in MS-based proteomics will further strengthen our position integrating experiments and bioinformatics in our service offerings."

Dr. Le Bihan received his Ph.D. in Chemistry/Biophysics at Université Laval in Quebec City. He has published in leading peer-review journals such as Nature and PNAS, and has presented talks at international conferences.  

About Rapid Novor Inc.

Rapid Novor Inc. is the world's leader in antibody protein sequencing technology. Specializing in the field of mass spectrometry-based proteomics, the team has developed the technology to directly sequence antibody proteins without needing to access the producing cell line. As a University of Waterloo spin-off, the company is building its technology portfolios based on the twenty years of scientific research and inventions from Dr. Bin Ma, co-founder and chief scientist. The company's REmAb™ antibody protein sequencing service has allowed for the accurate sequencing of any given antibody protein on a routine basis. The company's WILD™ service is the first commercially available service that can accurately distinguish the isomeric Isoleucine and Leucine using mass spectrometry. For more information, visit www.rapidnovor.com. Follow the company on Twitter @rapidnovor. 

Media Contact: Mingjie Xie, Rapid Novor Inc, +1 (519) 593-2260, mxie@rapidnovor.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


SOURCE Rapid Novor Inc



Biotechnology, Health Care & Hospitals, Medical Equipment, Personnel Announcements

More by this company

Need Help